The U.S. House last night passed a $1.5 trillion omnibus appropriations bill with language to help hospitals whose admission patterns have been so disrupted by COVID-19 that their Medicare disproportionate share (DSH) adjustment percentages have fallen below the levels needed
…
Pharmaceutical manufacturers Novo Nordisk and Sanofi on Tuesday laid out their cases for the next phase of the legal battle over their conditions on 340B pricing when covered entities use contract pharmacies. The cases are before the U.S. Court of
…
Drug manufacturer AbbVie had added its best-selling cancer medicine Imbruvica to its restrictions on 340B pricing when hospitals use contract pharmacies, effective April 1.
AbbVie contractor 340B ESP posted a policy update from AbbVie on its website on March 1.
…
Legislation addressing hospitals’ loss of eligibility for 340B drug discounts due to COVID-19-related changes in payer mix could reach President Biden before Friday at midnight. The language would not be as beneficial to such hospitals as standalone bipartisan bills in
…
Non-hospital 340B covered entities have formed a group called 340B Grantees to fight on their own behalf on legislation, in courts, and perhaps in politics at the federal and state levels.
340B Grantees hasn’t formally announced itself yet and is
…
It is time for Congress to make it crystal clear that contract pharmacies are integral to the 340B program, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell’s blog.
Federal courts have struck down federal
…
The American Hospital Association has asked U.S. Health and Human Services Secretary Xavier Becerra again to waive a requirement that it says is forcing hospitals out of the 340B program due to COVID-19-related changes in payer mix.
AHA President and
…
Drug manufacturer AstraZeneca and two health centers aligned with Ryan White Clinics for 340B Access (RWC-340B) briefed a 340B administrative dispute resolution (ADR) panel last week on whether a recent federal court ruling has implications for the health centers’ 340B
…
Nonprofit drug manufacturer Civica announced this morning that it plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at no more than $30 per vial and no more than $55 for a box
…
*Sign up for news summaries and alerts from 340B Report